Navigation Links
Cellectis bioresearch Announces the First TGCA Winner
Date:12/9/2010

PARIS, Dec. 9, 2010 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), has today announced the recipient of its post-doctoral fellowship award program. The Genome Customization Award (TGCA) is going to Dr Nelson Lau's research group, from the Department of Biology at the Brandeis University (Waltham, Massachusetts). The award was granted after thorough review of several very high profile applications for its outstanding research program on improving transgenesis of Xenopus tropicalis for RNA interference methodologies.

As the winning academic team, Dr Lau's research group will receive euro 15,000 (US$ 18,000) to partially fund for one year one post-doctoral fellow recruited to work on the project, with a possible renewal for a second year.

The award review committee selected Dr Nelson Lau's project based, in part, on its high probability of being successful. The project, which is focused on improving technologies in the model species Xenopus tropicalis, aims at

- Elucidating the rules of molecular specificity in shRNA design

- Applying custom meganucleases for improved transgenesis of the shRNA vector

- Expanding largely the technology

As a member of the same research institution, Prof. James Haber did not take part in the vote.

"We are delighted to be part of the endeavor to bring custom meganucleases to a new model organism where the technology has not been tested yet but has strong promise", stated Dr Nelson Lau.

"The investigator is a pre-eminent siRNA researcher who plans to use Cellectis' custom meganucleases in a very smart way," declared Prof. Rodney J. Rothstein of Columbia University, Chairman of the Committee.

The award will be officially presented to Dr Nelson Lau in March 2011 at the Grand Opening of Cellectis bioresearch Inc. facilities in Cambridge (Massachusetts) by Marc Le Bozec, CEO of Cellectis bioresearch.

The TGCA was established by Cellectis bioresearch in 2010 with the goal of spreading the use of meganucleases for genome customization throughout the Life Sciences community.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization.  These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional study. The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools - meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at www.cellectis.com

Follow Cellectis on Twitter at www.twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
2. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
3. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
4. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
5. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
6. Cellectis Unveils Its New Corporate Website
7. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
8. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
9. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
10. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
11. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a ... biotechnology industries to improve patient outcomes and quality of life, will now be ... are being attributed to new regulatory requirements for all new drug products, including ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Personal eye wash is a basic first aid ... at a time. So which eye do you rinse first if a dangerous substance enters ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its dirt ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
Breaking Biology Technology:
(Date:8/15/2017)... Aug. 15 2017   ivWatch LLC , a medical device ... therapy, today announced receipt of its ISO 13485 Certification, the global ... International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection of ... "This is an important milestone ...
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
Breaking Biology News(10 mins):